vs
REGENXBIO Inc.（RGNX）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Rumble Inc.的1.1倍（$30.3M vs $27.1M），Rumble Inc.净利率更高（-120.8% vs -221.3%，领先100.6%），REGENXBIO Inc.同比增速更快（43.0% vs -10.5%），Rumble Inc.自由现金流更多（$-31.7M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.2%）
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
RGNX vs RUM — 直观对比
营收规模更大
RGNX
是对方的1.1倍
$27.1M
营收增速更快
RGNX
高出53.5%
-10.5%
净利率更高
RUM
高出100.6%
-221.3%
自由现金流更多
RUM
多$21.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
15.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.3M | $27.1M |
| 净利润 | $-67.1M | $-32.7M |
| 毛利率 | — | 5.5% |
| 营业利润率 | -190.0% | -131.1% |
| 净利率 | -221.3% | -120.8% |
| 营收同比 | 43.0% | -10.5% |
| 净利润同比 | -31.2% | 86.2% |
| 每股收益（稀释后） | $-1.30 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGNXRUM
| Q4 25 | $30.3M | $27.1M | ||
| Q3 25 | $29.7M | $24.8M | ||
| Q2 25 | $21.4M | — | ||
| Q1 25 | $89.0M | $23.7M | ||
| Q4 24 | $21.2M | $30.2M | ||
| Q3 24 | $24.2M | $25.1M | ||
| Q2 24 | $22.3M | $22.5M | ||
| Q1 24 | $15.6M | $17.7M |
净利润RGNXRUM
| Q4 25 | $-67.1M | $-32.7M | ||
| Q3 25 | $-61.9M | $-16.3M | ||
| Q2 25 | $-70.9M | — | ||
| Q1 25 | $6.1M | $-2.7M | ||
| Q4 24 | $-51.2M | $-236.8M | ||
| Q3 24 | $-59.6M | $-31.5M | ||
| Q2 24 | $-53.0M | $-26.8M | ||
| Q1 24 | $-63.3M | $-43.3M |
毛利率RGNXRUM
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | 70.2% | -14.2% | ||
| Q3 24 | 48.8% | -45.4% | ||
| Q2 24 | 52.5% | -58.8% | ||
| Q1 24 | 72.6% | -79.5% |
营业利润率RGNXRUM
| Q4 25 | -190.0% | -131.1% | ||
| Q3 25 | -176.3% | -113.6% | ||
| Q2 25 | -296.3% | — | ||
| Q1 25 | 13.6% | -153.5% | ||
| Q4 24 | -242.1% | -80.1% | ||
| Q3 24 | -256.6% | -131.0% | ||
| Q2 24 | -251.3% | -172.7% | ||
| Q1 24 | -408.8% | -197.4% |
净利率RGNXRUM
| Q4 25 | -221.3% | -120.8% | ||
| Q3 25 | -208.3% | -65.7% | ||
| Q2 25 | -331.8% | — | ||
| Q1 25 | 6.8% | -11.2% | ||
| Q4 24 | -241.3% | -783.2% | ||
| Q3 24 | -246.3% | -125.9% | ||
| Q2 24 | -237.7% | -119.2% | ||
| Q1 24 | -405.4% | -244.1% |
每股收益（稀释后）RGNXRUM
| Q4 25 | $-1.30 | $-0.13 | ||
| Q3 25 | $-1.20 | $-0.06 | ||
| Q2 25 | $-1.38 | — | ||
| Q1 25 | $0.12 | $-0.01 | ||
| Q4 24 | $-0.99 | $-1.17 | ||
| Q3 24 | $-1.17 | $-0.15 | ||
| Q2 24 | $-1.05 | $-0.13 | ||
| Q1 24 | $-1.38 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.1M | $237.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $102.7M | $274.8M |
| 总资产 | $453.0M | $336.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RGNXRUM
| Q4 25 | $230.1M | $237.9M | ||
| Q3 25 | $274.2M | $269.8M | ||
| Q2 25 | $323.3M | — | ||
| Q1 25 | $267.9M | $301.3M | ||
| Q4 24 | $234.7M | $114.0M | ||
| Q3 24 | $255.5M | $132.0M | ||
| Q2 24 | $290.4M | $154.2M | ||
| Q1 24 | $338.7M | $183.8M |
股东权益RGNXRUM
| Q4 25 | $102.7M | $274.8M | ||
| Q3 25 | $161.5M | $302.2M | ||
| Q2 25 | $213.7M | — | ||
| Q1 25 | $274.2M | $339.6M | ||
| Q4 24 | $259.7M | $-63.1M | ||
| Q3 24 | $301.4M | $166.1M | ||
| Q2 24 | $348.3M | $192.7M | ||
| Q1 24 | $390.7M | $210.7M |
总资产RGNXRUM
| Q4 25 | $453.0M | $336.8M | ||
| Q3 25 | $525.2M | $367.2M | ||
| Q2 25 | $581.0M | — | ||
| Q1 25 | $490.9M | $391.1M | ||
| Q4 24 | $466.0M | $195.3M | ||
| Q3 24 | $519.1M | $217.2M | ||
| Q2 24 | $569.4M | $243.2M | ||
| Q1 24 | $629.2M | $263.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.3M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | $-52.8M | $-31.7M |
| 自由现金流率自由现金流/营收 | -174.0% | -117.2% |
| 资本支出强度资本支出/营收 | 1.7% | 8.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-126.4M | $-70.8M |
8季度趋势，按日历期对齐
经营现金流RGNXRUM
| Q4 25 | $-52.3M | $-29.4M | ||
| Q3 25 | $-56.0M | $-10.6M | ||
| Q2 25 | $-49.3M | — | ||
| Q1 25 | $33.6M | $-14.5M | ||
| Q4 24 | $-31.6M | $-12.4M | ||
| Q3 24 | $-40.5M | $-19.1M | ||
| Q2 24 | $-45.5M | $-21.7M | ||
| Q1 24 | $-55.5M | $-33.9M |
自由现金流RGNXRUM
| Q4 25 | $-52.8M | $-31.7M | ||
| Q3 25 | $-56.5M | $-12.0M | ||
| Q2 25 | $-49.7M | — | ||
| Q1 25 | $32.6M | $-14.6M | ||
| Q4 24 | $-32.7M | $-12.4M | ||
| Q3 24 | $-40.9M | $-19.9M | ||
| Q2 24 | $-46.0M | $-23.1M | ||
| Q1 24 | $-56.0M | $-34.3M |
自由现金流率RGNXRUM
| Q4 25 | -174.0% | -117.2% | ||
| Q3 25 | -189.9% | -48.6% | ||
| Q2 25 | -232.8% | — | ||
| Q1 25 | 36.6% | -61.7% | ||
| Q4 24 | -154.2% | -40.9% | ||
| Q3 24 | -168.9% | -79.5% | ||
| Q2 24 | -206.2% | -102.8% | ||
| Q1 24 | -358.5% | -193.3% |
资本支出强度RGNXRUM
| Q4 25 | 1.7% | 8.5% | ||
| Q3 25 | 1.7% | 5.7% | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.2% | 0.6% | ||
| Q4 24 | 5.1% | 0.1% | ||
| Q3 24 | 1.3% | 3.4% | ||
| Q2 24 | 2.1% | 6.1% | ||
| Q1 24 | 3.6% | 2.4% |
现金转化率RGNXRUM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 5.53× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
